Myeloma cells treated with low doses of therapeutic agents commonly used in the management of patients with multiple myeloma, such as doxorubicin, melphalan, and bortezomib, up-regulate NK cell-activating ligands for the NKG2D and DNAM-1 receptors, increasing NK cell degranulation in vitro and in vivo, an effect preferentially associated with SnCs arrested in the G2 phase of the cell cycle [50, 51]. This evidence concerns the gene KLRK1 and plasma cell myeloma.